Model: LC02-Q8; Specification: 8 Tests
The lung cancer core 11-gene variation combined detection product independently developed by TargetingOne covers all drug-related core genes recommended by authoritative medical guidelines such as NCCN and CSCO.Based on the digital PCR detection platform and through the two-dimensional detection of "DNA + RNA", it comprehensively screens for hotspot mutations in the core driver genes of non-small cell lung cancer (NSCLC), accurately guides targeted therapy for NSCLC patients, and provides clinics with a core, accurate, economical and rapid solution.
Product Features
Core: Selected as a first:line essentialtestfor lung cancer driver genesrecommended byauthoritative medical guidelines such as NCCN and CSCO.
Precision: Covers 100+ NSCLC drug targets with a stable detection limit as low as O.5%, Uilizes "DNA + RNA" dual-dimensional testing to ensureaccurate results.
Efficiency: Requires minimal sample usage, only3-8 slices, making it especially suitable for small or microsample.
Quick: Easy to operate, short reporting cycle, meeting the urgent needs of clinical diagnosis and treatment.
